查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1697361

抗病毒药物市场：未来预测（2025-2030）

Anti-Viral Drug Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计全球抗病毒药物市场规模将从 2025 年的 861 亿美元成长至 2030 年的 1,082.63 亿美元，预测期内复合年增长率将达到 4.69%。

抗病毒药物用于治疗流感。如果确实罹患流感，抗病毒药物可以帮助减轻发烧和流感症状，如咳嗽、喉咙痛、流鼻水或鼻塞、身体疼痛、头痛、发冷和疲倦。由于世界各国流感疫情日益流行，全球抗病毒药物市场正在成长。此外，全球老年人口的成长和政府措施的活性化也是预测期内推动抗病毒药物市场成长的主要因素。

市场趋势：

  • 全球流感病例数上升：全球流感病例数上升是抗病毒药物需求增加的主要因素。根据世界卫生组织统计，季节性流感每年导致300万至500万重症患者，29万至65万例呼吸道相关死亡病例。
  • 全球疫苗接种的增加：全球范围内疫苗的使用正在不断扩大，以改善公共卫生并减少潜在的大流行性流感的传播，各国政府正在加强提高人们对疫苗接种重要性的认识。
  • 北美：由于製药公司进行了广泛的研究和开发，北美很可能占据抗病毒药物市场的很大一部分。其背景是行业主要参与者的存在以及尖端医疗治疗方法的早期采用。
  • 欧洲：预计预测期内欧洲市场将大幅成长。这种快速成长很大程度上归功于政府倡议加强加速药品和疫苗的研发。
  • 亚太地区：预计亚太地区将经历快速成长，主要原因是流感和爱滋病毒诊断数量的增加。这一趋势正在推动印度和中国等人口大国使用抗病毒药物。

报告中介绍的主要公司包括 F. Hoffmann-La Roche Ltd、Gilead Sciences, Inc.、Bristol-Myers Squibb Company、Pfizer Inc.、AstraZeneca plc.、AbbVie Inc.、Johnson & Johnson、Merck &Co, Inc.、Atea Pharmaceuticals 和 GlaxoSmithKline plc。

本报告的主要优点

  • 深刻分析：获得涵盖主要地区和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 适用范围广：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024）和预测资料（2025-2030）
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按部门和地区（国家）分類的收益成长和预测分析
  • 公司概况（策略、产品、财务资讯、主要趋势等）

全球抗病毒药物市场按以下部分分析：

按使用类型

  • 抗疱疹病毒药物
  • 抗肝炎病毒药物
  • 抗病毒药物
  • 抗流感病毒药物
  • 其他抗病毒药物

按作用机制

  • 核苷酸聚合酵素抑制剂
  • 逆转录酶抑制剂
  • 蛋白酶抑制剂
  • 其他的

按分销管道

  • 在线的
  • 离线

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 美国英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 台湾
  • 其他的

目录

第一章执行摘要

第二章 市场概述

  • 市场概览
  • 市场定义
  • 研究范围
  • 市场区隔

第三章 商业景气

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

  • 产品平臺
  • 专利分析

第五章全球抗病毒药物市场按应用类型

  • 介绍
  • 抗疱疹抗病毒药物
  • 抗肝炎病毒药物
  • 抗病毒药物
  • 抗流感病毒药物
  • 其他抗病毒药物

6. 全球抗病毒药物市场（依作用机制）

  • 介绍
  • 核苷酸聚合酵素抑制剂
  • 逆转录酶抑制剂
  • 蛋白酶抑制剂
  • 其他的

7. 全球抗病毒药物市场（按分销管道）

  • 介绍
  • 在线的
  • 离线

8. 全球抗病毒药物市场（按地区）

  • 介绍
  • 北美洲
    • 按使用类型
    • 按作用机制
    • 按分销管道
    • 按国家
  • 南美洲
    • 按使用类型
    • 按作用机制
    • 按分销管道
    • 按国家
  • 欧洲
    • 按使用类型
    • 按作用机制
    • 按分销管道
    • 按国家
  • 中东和非洲
    • 按使用类型
    • 按作用机制
    • 按分销管道
    • 按国家
  • 亚太地区
    • 按使用类型
    • 按作用机制
    • 按分销管道
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 企业合併、协议、商业合作
  • 竞争仪錶板

第十章 公司简介

  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • AstraZeneca plc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Atea Pharmaceuticals
  • GlaxoSmithKline plc.

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061613444

The Global Anti-Viral Drug market is set to witness robust growth at a CAGR of 4.69% during the forecast period, worth US$ 108.263 billion in 2030 from US$ 86.100 billion in 2025.

Anti-viral drugs are used for treating influenza. When a flu illness develops, anti-viral medications can help reduce fever and flu symptoms such as cough, sore throat, runny or stuffy nose, body aches, headache, chills, and fatigue. The global anti-viral drug market is increasing due to the rising prevalence of influenza across various countries worldwide. The increasing geriatric population across the globe and increasing government initiatives are also among the major factors propelling the growth of the anti-viral drug market during the forecasted timeline.

Market Trends:

  • Rising influenza cases globally: The growing number of influenza cases worldwide is a key driver behind the increased demand for anti-viral drugs. The World Health Organization (WHO) reports that seasonal influenza causes 3 to 5 million severe illnesses annually, resulting in 290,000 to 650,000 respiratory-related deaths.
  • Increased global vaccine uptake: The expanding use of vaccines worldwide to enhance public health and curb the spread of flu, which has the potential to trigger pandemics, is encouraging governments to intensify efforts in raising awareness about the importance of vaccination.
  • North America: North America is poised to hold a substantial portion of the anti-viral drug market, driven by extensive research and development from pharmaceutical companies. This is supported by the presence of major industry players and the region's early adoption of cutting-edge medical treatments.
  • Europe: The European market is projected to experience significant growth over the forecast period. This surge is largely fueled by heightened government initiatives focused on advancing research and development for drugs and vaccines.
  • Asia Pacific: The Asia Pacific region is anticipated to see rapid growth, primarily due to the rising incidence of influenza and HIV diagnoses. This trend is boosting the use of anti-viral drugs in populous nations such as India and China.

Some of the major players covered in this report F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca plc., AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., Atea Pharmaceuticals, GlaxoSmithKline plc., among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Global Anti-Viral Drug Market is analyzed into the following segments:

By Application Type

  • Herpes Antiviral Drugs
  • Hepatitis Antiviral Drugs
  • HIV Antiviral Drugs
  • Influenza Antiviral Drugs
  • Other Anti-viral Drugs

By Mechanism of Action

  • Nucleotide Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

  • 4.1. Product Pipeline
  • 4.2. Patent Analysis

5. GLOBAL ANTI-VIRAL DRUG MARKET BY APPLICATION TYPE

  • 5.1. Introduction
  • 5.2. Herpes Antiviral Drugs
  • 5.3. Hepatitis Antiviral Drugs
  • 5.4. HIV Antiviral Drugs
  • 5.5. Influenza Antiviral Drugs
  • 5.6. Other Anti-viral Drugs

6. GLOBAL ANTI-VIRAL DRUG MARKET BY MECHANISM OF ACTION

  • 6.1. Introduction
  • 6.2. Nucleotide Polymerase Inhibitors
  • 6.3. Reverse Transcriptase Inhibitors
  • 6.4. Protease Inhibitors
  • 6.5. Others

7. GLOBAL ANTI-VIRAL DRUG MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Online
  • 7.3. Offline

8. GLOBAL ANTI-VIRAL DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Application Type
    • 8.2.2. By Mechanism of Action
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Application Type
    • 8.3.2. By Mechanism of Action
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Application Type
    • 8.4.2. By Mechanism of Action
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Application Type
    • 8.5.2. By Mechanism of Action
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Application Type
    • 8.6.2. By Mechanism of Action
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. F. Hoffmann-La Roche Ltd
  • 10.2. Gilead Sciences, Inc.
  • 10.3. Bristol-Myers Squibb Company
  • 10.4. Pfizer Inc.
  • 10.5. AstraZeneca plc.
  • 10.6. AbbVie Inc.
  • 10.7. Johnson & Johnson
  • 10.8. Merck & Co., Inc.
  • 10.9. Atea Pharmaceuticals
  • 10.10. GlaxoSmithKline plc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations